From: PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome
Mutational status
Patients N (%)
Overall survival
Median (months)
% at 5y
HR
P
PDGFR-A13
· WT (AA)
60 (82%)
37.1
14%
0.96
0.934
· SNP (AG)
13 (18%)
21.7
41%
PDGFR-B19
33 (42%)
NR
51%
1.93
0.073
· SNP (AG,GG)
45 (58%)
17%